Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more
Tissue Regenix Group Plc (TRX) - Net Assets
Latest net assets as of June 2025: GBX28.62 Million GBX
Based on the latest financial reports, Tissue Regenix Group Plc (TRX) has net assets worth GBX28.62 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX47.19 Million) and total liabilities (GBX18.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX28.62 Million |
| % of Total Assets | 60.66% |
| Annual Growth Rate | 9.48% |
| 5-Year Change | 4.34% |
| 10-Year Change | 151.87% |
| Growth Volatility | 107.92 |
Tissue Regenix Group Plc - Net Assets Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tissue Regenix Group Plc (2007–2024)
The table below shows the annual net assets of Tissue Regenix Group Plc from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX29.06 Million | -1.02% |
| 2023-12-31 | GBX29.36 Million | +16.15% |
| 2022-12-31 | GBX25.27 Million | +2.51% |
| 2021-12-31 | GBX24.65 Million | -11.47% |
| 2020-12-31 | GBX27.85 Million | +13.22% |
| 2019-12-31 | GBX24.59 Million | -24.49% |
| 2018-12-31 | GBX32.57 Million | -17.59% |
| 2018-01-31 | GBX39.52 Million | 0.00% |
| 2017-12-31 | GBX39.52 Million | +242.60% |
| 2016-12-31 | GBX11.54 Million | -61.86% |
| 2016-01-31 | GBX30.25 Million | +161.26% |
| 2015-01-31 | GBX11.58 Million | -63.01% |
| 2014-01-31 | GBX31.30 Million | -18.99% |
| 2013-01-31 | GBX38.64 Million | -11.73% |
| 2012-01-31 | GBX43.78 Million | +344.90% |
| 2011-01-31 | GBX9.84 Million | +168.38% |
| 2010-01-31 | GBX3.67 Million | +0.87% |
| 2009-01-31 | GBX3.63 Million | -62.46% |
| 2008-01-31 | GBX9.68 Million | +68.84% |
| 2007-01-31 | GBX5.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tissue Regenix Group Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12409500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX92.00K | 0.31% |
| Other Comprehensive Income | GBX20.72 Million | 69.50% |
| Other Components | GBX133.10 Million | 446.36% |
| Total Equity | GBX29.82 Million | 100.00% |
Tissue Regenix Group Plc Competitors by Market Cap
The table below lists competitors of Tissue Regenix Group Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amreli Steels Ltd
KAR:ASTL
|
$507.36 |
|
Ghani Gases Ltd
KAR:GGL
|
$507.42 |
|
Onion Global Limited
PINK:OGBLY
|
$507.81 |
|
POU SHENG INTL
BE:P5C
|
$508.01 |
|
Integrated Micro-Electronics Inc
PSE:IMI
|
$506.24 |
|
Dewan Farooque Motors Ltd
KAR:DFML
|
$505.90 |
|
AEON STORES (HK)
MU:AVK1
|
$505.78 |
|
HELMA EIGENHEIMBAU - Dusseldorf Stock Exchang
DU:H5E
|
$504.69 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tissue Regenix Group Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,150,000 to 29,819,000, a change of -331,000 (-1.1%).
- Net loss of 713,000 reduced equity.
- New share issuances of 104,000 increased equity.
- Other comprehensive income increased equity by 21,252,494.
- Other factors decreased equity by 20,974,494.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-713.00K | -2.39% |
| Share Issuances | GBX104.00K | +0.35% |
| Other Comprehensive Income | GBX21.25 Million | +71.27% |
| Other Changes | GBX-20.97 Million | -70.34% |
| Total Change | GBX- | -1.10% |
Book Value vs Market Value Analysis
This analysis compares Tissue Regenix Group Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-01-31 | GBX10.62 | GBX0.07 | x |
| 2009-01-31 | GBX3.03 | GBX0.07 | x |
| 2010-01-31 | GBX3.06 | GBX0.07 | x |
| 2011-01-31 | GBX2.69 | GBX0.07 | x |
| 2012-01-31 | GBX9.33 | GBX0.07 | x |
| 2013-01-31 | GBX6.08 | GBX0.07 | x |
| 2014-01-31 | GBX4.93 | GBX0.07 | x |
| 2015-01-31 | GBX1.82 | GBX0.07 | x |
| 2016-01-31 | GBX4.09 | GBX0.07 | x |
| 2017-12-31 | GBX4.34 | GBX0.07 | x |
| 2018-01-31 | GBX0.04 | GBX0.07 | x |
| 2018-12-31 | GBX2.82 | GBX0.07 | x |
| 2019-12-31 | GBX2.15 | GBX0.07 | x |
| 2020-12-31 | GBX0.64 | GBX0.07 | x |
| 2021-12-31 | GBX0.36 | GBX0.07 | x |
| 2022-12-31 | GBX0.44 | GBX0.07 | x |
| 2023-12-31 | GBX0.43 | GBX0.07 | x |
| 2024-12-31 | GBX0.42 | GBX0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tissue Regenix Group Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.49%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.52x
- Recent ROE (-2.39%) is above the historical average (-32.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -1.29% | -900.04% | 0.00x | 1.01x | GBX-1.09 Million |
| 2009 | -93.10% | -18800.91% | 0.00x | 1.02x | GBX-3.75 Million |
| 2010 | -9.89% | 0.00% | 0.00x | 1.01x | GBX-729.30K |
| 2011 | -87.28% | -4964.31% | 0.02x | 1.04x | GBX-9.57 Million |
| 2012 | -9.64% | -3871.01% | 0.00x | 1.02x | GBX-8.60 Million |
| 2013 | -14.30% | -7138.84% | 0.00x | 1.03x | GBX-9.39 Million |
| 2014 | -29.47% | -93216.67% | 0.00x | 1.06x | GBX-12.36 Million |
| 2015 | -65.48% | -7581.00% | 0.01x | 1.09x | GBX-8.74 Million |
| 2016 | -44.13% | -1153.19% | 0.04x | 1.09x | GBX-16.44 Million |
| 2016 | -90.90% | -678.17% | 0.12x | 1.16x | GBX-11.85 Million |
| 2017 | -23.09% | -176.21% | 0.11x | 1.15x | GBX-13.21 Million |
| 2018 | -23.09% | -176.21% | 0.11x | 1.15x | GBX-13.21 Million |
| 2018 | -24.77% | -70.45% | 0.31x | 1.14x | GBX-11.49 Million |
| 2019 | -27.66% | -53.50% | 0.43x | 1.21x | GBX-9.49 Million |
| 2020 | -34.11% | -75.68% | 0.35x | 1.29x | GBX-12.56 Million |
| 2021 | -18.90% | -24.27% | 0.58x | 1.35x | GBX-7.33 Million |
| 2022 | -8.62% | -11.01% | 0.64x | 1.22x | GBX-5.82 Million |
| 2023 | -5.68% | -5.81% | 0.68x | 1.43x | GBX-4.73 Million |
| 2024 | -2.39% | -2.49% | 0.63x | 1.52x | GBX-3.69 Million |
Industry Comparison
This section compares Tissue Regenix Group Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tissue Regenix Group Plc (TRX) | GBX28.62 Million | -1.29% | 0.65x | $507.31 |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |